Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 2
1957 1
1961 1
1963 1
1969 1
1970 2
1974 1
1976 1
1977 1
1979 1
1984 1
1985 1
1988 1
1989 2
1990 1
1992 3
1994 1
1997 1
1999 2
2006 2
2008 2
2009 2
2010 3
2011 2
2012 1
2014 1
2015 5
2016 6
2017 8
2018 13
2019 19
2020 11
2021 10
2022 13
2023 6
2024 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Hug C, Huynh-Ba O, Johnson J, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Diaz-Manera J, et al. Lancet Neurol. 2021 Dec;20(12):1012-1026. doi: 10.1016/S1474-4422(21)00241-6. Lancet Neurol. 2021. PMID: 34800399 Clinical Trial.
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
Kishnani PS, Diaz-Manera J, Toscano A, Clemens PR, Ladha S, Berger KI, Kushlaf H, Straub V, Carvalho G, Mozaffar T, Roberts M, Attarian S, Chien YH, Choi YC, Day JW, Erdem-Ozdamar S, Illarioshkin S, Goker-Alpan O, Kostera-Pruszczyk A, van der Ploeg AT, An Haack K, Huynh-Ba O, Tammireddy S, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Kishnani PS, et al. JAMA Neurol. 2023 Jun 1;80(6):558-567. doi: 10.1001/jamaneurol.2023.0552. JAMA Neurol. 2023. PMID: 37036722 Free PMC article. Clinical Trial.
The Neurobiology of Intervention and Prevention in Early Adversity.
Fisher PA, Beauchamp KG, Roos LE, Noll LK, Flannery J, Delker BC. Fisher PA, et al. Among authors: noll lk. Annu Rev Clin Psychol. 2016;12:331-57. doi: 10.1146/annurev-clinpsy-032814-112855. Epub 2015 Dec 7. Annu Rev Clin Psychol. 2016. PMID: 26666968 Review.
Validation of a real-time PCR panel for detection and quantification of nine pathogens commonly associated with canine infectious respiratory disease.
Dong J, Tsui WNT, Leng X, Fu J, Lohman M, Anderson J, Hamill V, Lu N, Porter EP, Gray M, Sebhatu T, Brown S, Pogranichniy R, Wang H, Noll L, Bai J. Dong J, et al. Among authors: noll l. MethodsX. 2023 Nov 11;11:102476. doi: 10.1016/j.mex.2023.102476. eCollection 2023 Dec. MethodsX. 2023. PMID: 38053622 Free PMC article.
Maladaptive behaviors in individuals with Angelman syndrome.
Sadhwani A, Willen JM, LaVallee N, Stepanians M, Miller H, Peters SU, Barbieri-Welge RL, Horowitz LT, Noll LM, Hundley RJ, Bird LM, Tan WH. Sadhwani A, et al. Among authors: noll lm. Am J Med Genet A. 2019 Jun;179(6):983-992. doi: 10.1002/ajmg.a.61140. Epub 2019 Apr 3. Am J Med Genet A. 2019. PMID: 30942555 Free PMC article.
122 results